IFN-α kinoid疫苗治疗系统性红斑狼疮的IIb期随机安慰剂对照研究
该IIb期随机双盲安慰剂对照试验纳入185例中重度活动性且干扰素基因特征阳性的SLE患者,评估IFN-K疫苗的疗效与安全性。IFN-K在91%患者中诱导抗IFN-α2b中和抗体并显著降低干扰素基因特征,但共同主要终点改良BICLA未达统计学差异;LLDAS达标率和激素减量等次要终点显著优于安慰剂。
要点
- IFN-K在91%患者中诱导中和性抗IFN-α2b抗体并显著降低IFN基因特征(p<0.0001)。
- W36改良BICLA应答率IFN-K组41% vs 安慰剂组34%,差异无统计学意义。
- IFN-K组LLDAS达标率53% vs 30%(p=0.0022),且自W28起显著减少泼尼松用量。
核心结论
- IFN-K可诱导中和性抗IFN-α2b抗体并显著降低IFN基因特征,安全性可接受。
- 共同主要临床终点未达到,但LLDAS达标和激素减量等次要终点显著获益。
研究设计与样本
- 36周IIb期随机双盲安慰剂对照试验,纳入185例中重度活动性、IFN基因特征阳性的成人SLE患者。
- IFN-K或安慰剂肌肉注射于第0、7、28天及第12、24周给药。
主要发现
- IFN-K在91%治疗患者中诱导中和性抗IFN-α2b血清抗体,并降低IFN基因特征(p<0.0001)。
- W36改良BICLA应答率IFN-K组41%、安慰剂组34%,无统计学差异。
- W36 LLDAS达标率IFN-K组53% vs 安慰剂组30%(p=0.0022)。
- 自W28起观察到IFN-K显著激素节约效应,W36泼尼松日剂量较安慰剂组减少24%(p=0.0097)。
- 在产生中和性抗IFN-α2b抗体的患者中,SRI-4(含激素减量)分析 favour IFN-K且差异显著(p<0.05)。
关键数值与推荐
- 共同主要终点为W36 IFN基因特征中和及强制激素减量的改良BICLA应答。
- LLDAS在W36的组间比较为53% vs 30%(p=0.0022)。
- W36泼尼松日剂量IFN-K组较安慰剂组减少24%(p=0.0097)。
临床怎么用
- 对于IFN基因特征阳性的活动性SLE患者,IFN-K可能有助于实现LLDAS和减少糖皮质激素用量。
- 治疗决策需权衡其未达共同主要临床终点与次要终点获益之间的差异。
局限性
- 共同主要临床终点改良BICLA未达到统计学差异。
- SRI-4的显著获益仅在产生中和性抗IFN-α2b抗体的患者亚组中观察到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of the immunotherapeutic vaccine interferon-α kinoid (IFN-K) in a 36-week (W) phase IIb, randomised, double-blind, placebo (PBO)-controlled trial in adults with active systemic lupus erythematosus (SLE) despite standard of care. METHODS: Patients with SLE (185) with moderate to severe disease activity and positive interferon (IFN) gene signature were randomised to receive IFN-K or PBO intramuscular injections (days 0, 7 and 28 and W12 and W24). Coprimary endpoints at W36 were neutralisation of IFN gene signature and the BILAG-Based Composite Lupus Assessment (BICLA) modified by mandatory corticosteroid (CS) tapering. RESULTS: IFN-K induced neutralising anti-IFN-α2b serum antibodies in 91% of treated patients and reduced the IFN gene signature (p<0.0001). Modified BICLA responses at W36 did not statistically differ between IFN-K (41%) and PBO (34%). Trends on Systemic Lupus Erythematosus Responder Index-4, including steroid tapering at W36, favoured the IFN-K and became significant (p<0.05) in analyses restricted to patients who developed neutralising anti-IFN-α2b antibodies. Attainment of lupus low disease activity state (LLDAS) at W36 discriminated the two groups in favour of IFN-K (53% vs 30%, p=0.0022). A significant CS sparing effect of IFN-K was observed from W28 onwards, with a 24% prednisone daily dose reduction at W36 in IFN-K compared with PBO (p=0.0097). The safety profile of IFN-K was acceptable. CONCLUSIONS: IFN-K induced neutralising anti-IFN-α2b antibodies and significantly reduced the IFN gene signature with an acceptable safety profile. Although the clinical coprimary endpoint was not met, relevant secondary endpoints were achieved in the IFN-K group, including attainment of LLDAS and steroid tapering. TRIAL REGISTRATION NUMBER: NCT02665364.
引用
- Houssiau FA, Thanou A, Mazur M, et al. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2019. PMID: 31871140. doi:10.1136/annrheumdis-2019-216379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。